The effects of testosterone on body composition in obese men are not sustained after cessation of testosterone treatment

M Ng Tang Fui; R Hoermann; JD Zajac; M Grossmann

Journal article

The effects of testosterone on body composition in obese men are not sustained after cessation of testosterone treatment

M Ng Tang Fui, R Hoermann, JD Zajac, M Grossmann

Clinical Endocrinology | WILEY | Published : 2017

DOI: 10.1111/cen.13385

Download PDF

Abstract

Background: Testosterone treatment in obese dieting men augments the diet-associated loss of fat mass, but protects against loss of lean mass. We assessed whether body composition changes are maintained following withdrawal of testosterone treatment. Methods: We conducted a prespecified double-blind randomized placebo-controlled observational follow-up study of a randomized controlled trial (RCT). Participants were men with baseline obesity (body mass index >30 kg/m2) and a repeated total testosterone level <12 nmol/L, previously enrolled in a 56-week testosterone treatment trial combined with a weight loss programme. Main outcome measures were mean adjusted differences (MAD) (95% confidence..

View full abstract

University of Melbourne Researchers

Mark Ng Tang Fui Author

Jeffrey Zajac Author

Mathis Grossmann Author

Related Projects (2)

A CLINICAL TRIAL TO ASSESS THE EFFECT OF TESTOSTERONE TREATMENT COMBINED WITH DIETARY RESTRICTION ON BODY FAT MASS AND MUSCLE FUNCTION IN OBESE MEN

Obesity, an increasing health and economic burden, is associated with lowered testosterone levels in men. While both dietary restriction and..

CONTROL OF MUSCULOSKELETAL FUNCTION AND INSULIN RESISTANCE BY ANDROGENS IN MALES

Male sex hormone or androgen deficiency (AD) is a common, but under-diagnosed condition. AD decreases general well being and contributes to ..

Grants

Funding Acknowledgements

MNTF was supported by a postgraduate scholarship (1055305) and MG by a Career Development Fellowship (1024139) both from the National Health and Medical Research Council (Australia). Bayer Pharma AG (Berlin, Germany) provided testosterone, placebo and financial support to conduct investigations during the RCT phase, but did not provide funding for this observational follow-up study. Bayer Pharma AG had no role in trial design, data analysis or writing the manuscript.